Qualigen Therapeutics (QLGN) Competitors $2.80 -0.10 (-3.45%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.82 +0.02 (+0.75%) As of 07/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QLGN vs. SONN, MRKR, RVPH, RLMD, BLRX, LEXX, IXHL, RLYB, ASBP, and VYNEShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Sonnet BioTherapeutics (SONN), MARKER THERAPEUTICS (MRKR), Reviva Pharmaceuticals (RVPH), Relmada Therapeutics (RLMD), BioLineRx (BLRX), Lexaria Bioscience (LEXX), Incannex Healthcare (IXHL), Rallybio (RLYB), Aspire Biopharma (ASBP), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. Its Competitors Sonnet BioTherapeutics MARKER THERAPEUTICS Reviva Pharmaceuticals Relmada Therapeutics BioLineRx Lexaria Bioscience Incannex Healthcare Rallybio Aspire Biopharma VYNE Therapeutics Sonnet BioTherapeutics (NASDAQ:SONN) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation. Which has more risk & volatility, SONN or QLGN? Sonnet BioTherapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Is SONN or QLGN more profitable? Qualigen Therapeutics' return on equity of 0.00% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sonnet BioTherapeuticsN/A -777.92% -271.32% Qualigen Therapeutics N/A N/A N/A Do analysts rate SONN or QLGN? Sonnet BioTherapeutics presently has a consensus target price of $20.00, indicating a potential upside of 401.25%. Given Sonnet BioTherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Sonnet BioTherapeutics is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, SONN or QLGN? Qualigen Therapeutics has lower revenue, but higher earnings than Sonnet BioTherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonnet BioTherapeutics$1M12.63-$7.44MN/AN/AQualigen TherapeuticsN/AN/A-$6.26MN/AN/A Do institutionals and insiders have more ownership in SONN or QLGN? 9.4% of Sonnet BioTherapeutics shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor SONN or QLGN? In the previous week, Qualigen Therapeutics had 1 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 1 mentions for Sonnet BioTherapeutics. Sonnet BioTherapeutics' average media sentiment score of 1.87 beat Qualigen Therapeutics' score of 1.63 indicating that Sonnet BioTherapeutics is being referred to more favorably in the media. Company Overall Sentiment Sonnet BioTherapeutics Very Positive Qualigen Therapeutics Very Positive SummarySonnet BioTherapeutics beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks. Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.75M$2.50B$5.70B$9.50BDividend YieldN/A1.75%4.69%4.01%P/E RatioN/A9.0528.1020.06Price / SalesN/A592.38428.7189.10Price / CashN/A165.2136.2258.56Price / Book-0.685.168.665.87Net Income-$6.26M$30.99M$3.25B$258.55M7 Day Performance-6.98%7.74%4.22%3.73%1 Month Performance-20.90%16.27%10.51%11.75%1 Year Performance-76.55%-1.88%34.40%18.02% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$2.80-3.4%N/A-77.8%$4.75MN/A0.0050Earnings ReportGap DownSONNSonnet BioTherapeutics3.9663 of 5 stars$5.15-16.7%$20.00+288.3%-41.3%$19.57M$20K0.0010Positive NewsGap DownMRKRMARKER THERAPEUTICS4.5448 of 5 stars$1.53-10.0%$13.17+760.6%-70.2%$19.24M$6.59M-1.1560Gap UpHigh Trading VolumeRVPHReviva Pharmaceuticals3.3798 of 5 stars$0.40-1.0%$9.00+2,176.8%-62.6%$19.16MN/A-0.505Positive NewsGap UpHigh Trading VolumeRLMDRelmada Therapeutics4.8117 of 5 stars$0.61+6.4%$5.00+714.3%-84.0%$19.15MN/A-0.2410Positive NewsGap DownBLRXBioLineRx2.7973 of 5 stars$4.36-2.5%$26.00+496.3%-87.8%$19.05M$28.94M-0.5040Positive NewsLEXXLexaria Bioscience2.2435 of 5 stars$0.95+1.0%$5.00+423.7%-68.3%$18.49M$460K-1.427IXHLIncannex Healthcare0.73 of 5 stars$0.82+34.4%N/A-51.4%$17.95M$10K-0.683News CoverageGap DownHigh Trading VolumeRLYBRallybio2.8586 of 5 stars$0.46+7.5%$10.00+2,063.1%-62.5%$17.89M$640K-0.4240Positive NewsASBPAspire BiopharmaN/A$0.41+14.1%N/AN/A$17.73MN/A0.00N/ANews CoverageGap DownVYNEVYNE Therapeutics2.9479 of 5 stars$1.21+4.3%$6.25+416.5%-30.5%$17.64M$500K-1.2230Positive NewsHigh Trading Volume Related Companies and Tools Related Companies SONN Competitors MRKR Competitors RVPH Competitors RLMD Competitors BLRX Competitors LEXX Competitors IXHL Competitors RLYB Competitors ASBP Competitors VYNE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QLGN) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhat I told my neighbor to do with his moneyWhen a close friend inherited money, Joel Litman gave him the same investment advice he gives his own mom. ...Altimetry | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
